{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:13:47Z","timestamp":1783574027649,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel therapies have achieved unprecedented benefit in survival of advanced melanoma patients. While immunotherapy (ICI) can be administered independent of mutational status, BRAF and MEK kinase inhibitors represent another effective treatment option for patients with BRAF mutant melanoma. Given the benefits these therapies demonstrate, the natural instinct was to combine. Three studies have investigated the benefit of combination of ICI using anti-PD-1 or anti-PD-L1 antibody and targeted therapy (TT) with BRAF and MEK inhibitors over TT and placebo. Among these studies, statistically significantly superior duration of response was observed, however overall and progression-free survival were only numerically superior, if at all. One triple combination was approved for BRAF mutant metastatic melanoma; however, the expected synergistic effect of triple therapy could not be universally confirmed and the observed benefits with triple seem to depend on statistical considerations rather than a biological reason. As patients with BRAF mutant melanoma have both ICI and TT as their first-line treatment options, the question whether the sequence matters was addressed. Two prospective trials compared first-line ICI, followed by TT at progression, or vice-versa, with additional \u201csandwich\u201d approach (8\u00a0weeks of TT followed by ICI until progression, then TT again) in the Secombit study. The benefit of first-line ICI was demonstrated in both studies with Secombit study showing the \u201csandwich\u201d approach to have similar effect. Current data advices for immunotherapy based regiments in patients with BRAF mutant melanoma or, possibly, sandwich approach. Whether triple therapy is superior to ICI monotherapy still needs to be addressed considering not only efficacy, but also safety.<\/jats:p>","DOI":"10.1186\/s12967-023-04391-1","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T06:01:41Z","timestamp":1691215301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study"],"prefix":"10.1186","volume":"21","author":[{"given":"Reinhard","family":"Dummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-8608","authenticated-orcid":false,"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"key":"4391_CR1","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.3390\/cancers14225489","volume":"14","author":"M Welti","year":"2022","unstructured":"Welti M, Dimitriou F, Gutzmer R, et al. Triple combination of immune checkpoint inhibitors and BRAF\/MEK inhibitors in BRAFV600 melanoma: current status and future perspectives. Cancers (Basel). 2022;14:5489.","journal-title":"Cancers (Basel)"},{"key":"4391_CR2","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1001\/jamaoncol.2020.4401","volume":"6","author":"R Dummer","year":"2020","unstructured":"Dummer R, Ascierto PA, Nathan P, et al. Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review. JAMA Oncol. 2020;6:1957\u201366.","journal-title":"JAMA Oncol"},{"key":"4391_CR3","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835\u201344.","journal-title":"Lancet"},{"key":"4391_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","volume":"25","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan RJ, Hamid O, Gonzalez R, et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019;25:929\u201335.","journal-title":"Nat Med"},{"key":"4391_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","volume":"24","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Stroyakovskiy D, Gogas H, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol. 2023;24:33\u201344.","journal-title":"Lancet Oncol"},{"key":"4391_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1470-2045(22)00452-1","volume":"23","author":"R Dummer","year":"2022","unstructured":"Dummer R, Queirolo P, Abajo Guijarro AM, et al. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2022;23:1145\u201355.","journal-title":"Lancet Oncol"},{"key":"4391_CR7","doi-asserted-by":"publisher","first-page":"E482-E","DOI":"10.1016\/S1470-2045(22)00647-7","volume":"23","author":"R Dummer","year":"2022","unstructured":"Dummer R, Tawbi H. Symptomatic melanoma CNS metastases in the TRICOTEL study. Lancet Oncol. 2022;23:E482-E.","journal-title":"Lancet Oncol"},{"key":"4391_CR8","doi-asserted-by":"publisher","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","volume":"8","author":"PF Ferrucci","year":"2020","unstructured":"Ferrucci PF, Di Giacomo AM, Del Vecchio M, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020;8:e001806.","journal-title":"J Immunother Cancer"},{"key":"4391_CR9","doi-asserted-by":"publisher","first-page":"9516","DOI":"10.1200\/JCO.2022.40.16_suppl.9516","volume":"40","author":"A Ribas","year":"2022","unstructured":"Ribas A, Ferrucci PF, Atkinson V, et al. Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E\/K-mutant melanoma: long-term follow-up of KEYNOTE-022 parts 1, 2, and 3. J Clin Oncol. 2022;40:9516.","journal-title":"J Clin Oncol"},{"key":"4391_CR10","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.21.01601","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Long GV, Robert C, et al. Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma. J Clin Oncol. 2022;40:1428\u201338.","journal-title":"J Clin Oncol"},{"key":"4391_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","volume":"25","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019;25:941\u20136.","journal-title":"Nat Med"},{"key":"4391_CR12","doi-asserted-by":"publisher","first-page":"9527","DOI":"10.1200\/JCO.2022.40.16_suppl.9527","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Long GV, Tawbi HA, et al. Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600\u2013mutant unresectable or metastatic melanoma: three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. J Clin Oncol. 2022;40:9527.","journal-title":"J Clin Oncol"},{"key":"4391_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2022","unstructured":"Ascierto PA, Mandala M, Ferrucci PF, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol. 2022;41:212.","journal-title":"J Clin Oncol"},{"key":"4391_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","volume":"2","author":"L Haas","year":"2021","unstructured":"Haas L, Elewaut A, Gerard CL, et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat Cancer. 2021;2:693\u2013708.","journal-title":"Nat Cancer"},{"key":"4391_CR15","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1136\/jitc-2022-004610","volume":"10","author":"I Pires da Silva","year":"2022","unstructured":"Pires da Silva I, Zakria D, Ahmed T, et al. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF\/MEK inhibitors in patients with BRAF mutant metastatic melanoma. J Immunother Cancer. 2022;10:4610.","journal-title":"J Immunother Cancer"},{"key":"4391_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2022","unstructured":"Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial\u2014ECOG-ACRIN EA6134. J Clin Oncol. 2022;41:186.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04391-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04391-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04391-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T08:19:11Z","timestamp":1700381951000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04391-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4391"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04391-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]},"assertion":[{"value":"19 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R. Dummer has intermittent, project focused consulting and\/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME outside the submitted work. M. Welti and E. Ramelyte have no conflicts of interest regarding this Commentary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"529"}}